Search research articles
Contact Us
Filters
Showing results (261-270 of 284) with videos related to
Page
of 29
Sort By:
Journal of the National Cancer Institute
|
January 26, 2018
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
Filippo Pietrantonio, Federica Di Nicolantonio, Alexa B Schrock, et al.
ESMO Open
|
August 30, 2017
Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)
Riccardo Ricotta, Antonella Verrioli, Silvia Ghezzi, et al.
Journal for Immunotherapy of Cancer
|
February 10, 2025
Sex and outcomes of patients with microsatellite instability-high and <i>BRAF</i> V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors
Vincenzo Nasca, Joseph Zhao, Javier Ros, et al.
Cancer Cell
|
January 17, 2025
A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer
Amelia Acha-Sagredo, Pietro Andrei, Kalum Clayton, et al.
Cancers
|
August 26, 2023
Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database
Fang-Shu Ou, Daniel H Ahn, Jesse G Dixon, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 19, 2024
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis
Romain Cohen, Morteza Raeisi, Benoist Chibaudel, et al.
La Radiologia Medica
|
July 7, 2026
Request and reporting models for computed tomography in the multidisciplinary management of cancer patients: consensus between the Italian Society of Medical and Interventional Radiology (SIRM) and the Italian Society of Medical Oncology (AIOM)
Vincenza Granata, Alessandro Serafini, Roberta Fusco, et al.
Annals of Surgery
|
December 1, 2022
Demystifying BRAF Mutation Status in Colorectal Liver Metastases : A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions
Georgios A Margonis, Thomas Boerner, Jean-Baptiste Bachet, et al.
Lancet (London, England)
|
June 18, 2023
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
Arvind Dasari, Sara Lonardi, Rocio Garcia-Carbonero, et al.
The Lancet. Oncology
|
March 14, 2020
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini, et al.
Page
of 29
Search research articles
Search
Showing results (261-270 of 284) with videos related to
Sort By:
Page
of 29
Journal of the National Cancer Institute
|
January 26, 2018
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
Filippo Pietrantonio, Federica Di Nicolantonio, Alexa B Schrock, et al.
ESMO Open
|
August 30, 2017
Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)
Riccardo Ricotta, Antonella Verrioli, Silvia Ghezzi, et al.
Journal for Immunotherapy of Cancer
|
February 10, 2025
Sex and outcomes of patients with microsatellite instability-high and <i>BRAF</i> V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors
Vincenzo Nasca, Joseph Zhao, Javier Ros, et al.
Cancer Cell
|
January 17, 2025
A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer
Amelia Acha-Sagredo, Pietro Andrei, Kalum Clayton, et al.
Cancers
|
August 26, 2023
Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database
Fang-Shu Ou, Daniel H Ahn, Jesse G Dixon, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 19, 2024
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis
Romain Cohen, Morteza Raeisi, Benoist Chibaudel, et al.
La Radiologia Medica
|
July 7, 2026
Request and reporting models for computed tomography in the multidisciplinary management of cancer patients: consensus between the Italian Society of Medical and Interventional Radiology (SIRM) and the Italian Society of Medical Oncology (AIOM)
Vincenza Granata, Alessandro Serafini, Roberta Fusco, et al.
Annals of Surgery
|
December 1, 2022
Demystifying BRAF Mutation Status in Colorectal Liver Metastases : A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions
Georgios A Margonis, Thomas Boerner, Jean-Baptiste Bachet, et al.
Lancet (London, England)
|
June 18, 2023
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
Arvind Dasari, Sara Lonardi, Rocio Garcia-Carbonero, et al.
The Lancet. Oncology
|
March 14, 2020
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini, et al.
Page
of 29